Shield Therapeutics Plc - Company & Market Research Reports

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of high unmet medical need. The company’s key products are Feraccru and PT20, one commercially available and one late-stage pharmaceutical for the treatment of iron deficiency anaemia and systemic phosphate accumulation. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

From
Drug Overview: Feraccru - Product Thumbnail Image

Drug Overview: Feraccru

  • Drug Pipelines
  • 15 Pages
From
Hyperphosphatemia - Pipeline Insight, 2018 - Product Thumbnail Image

Hyperphosphatemia - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
From
From
From
From
From
From
From
Shield Therapeutics PLC - Product Thumbnail Image

Shield Therapeutics PLC

  • Company Profile
  • 74 Pages
  • 19 Results (Page 1 of 1)
Loading Indicator
adroll